drugset / Trial / NCT03855865
Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)
RandomizedParallel-groupDouble-blindTreatment
Summary
The study will evaluate the efficacy, safety, and tolerability of 450 milligrams (mg) of Rapastinel, compared to 10 mg of Vortixetine and placebo in participants with major depressive disorder (MDD).
Timeline
- Start
- 2019-07-01
- Primary completion
- 2020-12-31
- Completion
- 2020-12-31
Outcome
Outcome not reported
Stopped (Business): “Business decision to stop the program.”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rapastinel | Other / unclassified | 450 mg | Intravenous |
| Comparator | Vortioxetine | Unknown | 10 mg | Oral |
| Comparator | Vortioxetine | Unknown | 20 mg | Oral |